These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9836448

  • 1. Inhibition of topoisomerases by antitumor prostaglandins.
    Suzuki K, Shono F, Uyeda M.
    Biosci Biotechnol Biochem; 1998 Oct; 62(10):2073-5. PubMed ID: 9836448
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory properties of antitumor prostaglandins against topoisomerases.
    Suzuki K, Uyeda M.
    Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandins in the treatment of cancer.
    Sasaki H, Fukushima M.
    Anticancer Drugs; 1994 Apr; 5(2):131-8. PubMed ID: 8049495
    [Abstract] [Full Text] [Related]

  • 4. Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins.
    Kikuchi Y, Kita T, Hirata J, Kuki E, Nagata I, Fukushima M.
    Int J Immunopharmacol; 1992 Jan; 14(1):105-10. PubMed ID: 1582730
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the proliferation of transformed epidermal cells in culture by various prostaglandins.
    Ikai K, Ujihara M, Kashihara M, Fukushima M.
    J Invest Dermatol; 1987 Jul; 89(1):69-72. PubMed ID: 2439606
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells.
    Kikuchi Y, Kita T, Miyauchi M, Hirata J, Sasa H, Nagata I, Fukushima M.
    J Cancer Res Clin Oncol; 1992 Jul; 118(6):453-7. PubMed ID: 1618893
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of DNA topoisomerases by nidulalin A derivatives.
    Sato S, Fukuda Y, Nakagawa R, Tsuji T, Umemura K, Andoh T.
    Biol Pharm Bull; 2000 Apr; 23(4):511-2. PubMed ID: 10784438
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preferential binding of growth inhibitory prostaglandins by the target protein of a carcinogen.
    Khan SH, Sorof S.
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9401-5. PubMed ID: 2251282
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents.
    ElAttar TM, Virji AS.
    Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):461-5. PubMed ID: 9223658
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ, Finlay GJ, Baguley BC.
    Cancer Chemother Pharmacol; 1999 Jun; 43(4):302-8. PubMed ID: 10071981
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of topoisomerases by fatty acids.
    Suzuki K, Shono F, Kai H, Uno T, Uyeda M.
    J Enzyme Inhib; 2000 Jun; 15(4):357-66. PubMed ID: 10995067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.